Last reviewed · How we verify
Fluval AB vaccination
Fluval AB vaccination is a Inactivated influenza vaccine Small molecule drug developed by Fluart Innovative Vaccine Ltd, Hungary. It is currently FDA-approved for Seasonal influenza A and B prevention in adults and children.
Fluval AB is an inactivated influenza A and B vaccine that stimulates the immune system to produce antibodies against seasonal influenza viruses.
Fluval AB is an inactivated influenza A and B vaccine that stimulates the immune system to produce antibodies against seasonal influenza viruses. Used for Seasonal influenza A and B prevention in adults and children.
At a glance
| Generic name | Fluval AB vaccination |
|---|---|
| Sponsor | Fluart Innovative Vaccine Ltd, Hungary |
| Drug class | Inactivated influenza vaccine |
| Modality | Small molecule |
| Therapeutic area | Immunology / Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
The vaccine contains inactivated (killed) influenza A and B virus antigens that trigger both humoral and cellular immune responses. Upon vaccination, the immune system recognizes these antigens and generates specific antibodies and memory cells that provide protection against infection with circulating influenza strains during the flu season.
Approved indications
- Seasonal influenza A and B prevention in adults and children
Common side effects
- Injection site pain, redness, or swelling
- Fever
- Myalgia
- Fatigue
- Headache
Key clinical trials
- Tolerability and Immunogenicity Study of Fluval AB Suspension for Injection (PHASE4)
- Immunogenicity and Tolerability Study of Fluval AB Novo Suspension for Injection for Children and Adolescents (PHASE3)
- Yearly Licence Tolerability and Immunogenicity Study of Fluval AB Seasonal Influenza Vaccine to be Used in the 2012/2013 Vaccination Season (PHASE4)
- Tolerability and Immunogenicity Study of FLUVAL P H1N1 Flu Vaccine of Omninvest in Children and Adolescents (NA)
- Tolerability and Immunogenicity Study of Fluval AB Influenza Vaccine in Adults and Elderly Persons (PHASE4)
- Safety and Immunogenicity Study of Fluval AB-Like Flu Vaccines With 3.5, 6, 9 or 15 μg HA in Adult and Elderly People (NA)
- A Study to Evaluate Safety and Immunogenicity of FluvalAB-like Influenza Vaccine in Non-Elderly Adult and Elderly Subjects (NA)
- Tolerability and Immunogenicity of Fluval P Monovalent Influenza Vaccine (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Fluval AB vaccination CI brief — competitive landscape report
- Fluval AB vaccination updates RSS · CI watch RSS
- Fluart Innovative Vaccine Ltd, Hungary portfolio CI
Frequently asked questions about Fluval AB vaccination
What is Fluval AB vaccination?
How does Fluval AB vaccination work?
What is Fluval AB vaccination used for?
Who makes Fluval AB vaccination?
What drug class is Fluval AB vaccination in?
What development phase is Fluval AB vaccination in?
What are the side effects of Fluval AB vaccination?
Related
- Drug class: All Inactivated influenza vaccine drugs
- Manufacturer: Fluart Innovative Vaccine Ltd, Hungary — full pipeline
- Therapeutic area: All drugs in Immunology / Infectious Disease
- Indication: Drugs for Seasonal influenza A and B prevention in adults and children
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing